Advances in structure-based vaccine design.
暂无分享,去创建一个
[1] R. Varadarajan,et al. Design of a Non-glycosylated Outer Domain-derived HIV-1 gp120 Immunogen That Binds to CD4 and Induces Neutralizing Antibodies* , 2010, The Journal of Biological Chemistry.
[2] J. Whittle,et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies , 2012, Nature.
[3] M. Bolognesi,et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections , 2011, Proceedings of the National Academy of Sciences.
[4] Jamie K. Scott,et al. Complex binding sites made to order , 2012, Nature Biotechnology.
[5] Shuzhao Li,et al. Systems vaccinology: learning to compute the behavior of vaccine induced immunity , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.
[6] Ron Diskin,et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.
[7] J. Heeney,et al. Viruses as vaccine vectors for infectious diseases and cancer , 2010, Nature Reviews Microbiology.
[8] D. Burton. Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.
[9] Eva K. Lee,et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.
[10] R. Varadarajan,et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.
[11] D. Montefiori,et al. Design of an Escherichia coli Expressed HIV-1 gp120 Fragment Immunogen That Binds to b12 and Induces Broad and Potent Neutralizing Antibodies , 2013, The Journal of Biological Chemistry.
[12] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[13] L. Stamatatos,et al. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. , 2010, Structure.
[14] Xavier Daura,et al. Exploiting Antigenic Diversity for Vaccine Design , 2010, The Journal of Biological Chemistry.
[15] B. Graham,et al. DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases , 2009, Human vaccines.
[16] S. Plotkin. Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.
[17] T. Schlake,et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection , 2012, Nature Biotechnology.
[18] S. Koide,et al. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. , 2005, Journal of molecular biology.
[19] Jens Meiler,et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. , 2011, Methods in enzymology.
[20] T. Kepler,et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies , 2013, The Journal of experimental medicine.
[21] J. Mascola,et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials , 2011, The Lancet Infectious Diseases.
[22] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[23] Boguslaw Stec,et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.
[24] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[25] C. Donati,et al. Reverse vaccinology in the 21st century: improvements over the original design , 2013, Annals of the New York Academy of Sciences.
[26] R. Varadarajan,et al. Design of Escherichia coli-Expressed Stalk Domain Immunogens of H1N1 Hemagglutinin That Protect Mice from Lethal Challenge , 2012, Journal of Virology.
[27] Ryo Takano,et al. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. , 2010, Antiviral research.
[28] A MarioCalvo,et al. Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .
[29] Q. Sattentau,et al. Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens , 2012, Nature Biotechnology.
[30] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[31] J. Julien,et al. Structural insights into key sites of vulnerability on HIV‐1 Env and influenza HA , 2012, Immunological reviews.
[32] Jeannette Adu-Bobie,et al. Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 , 2003, The Journal of experimental medicine.
[33] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[34] Y. Isegawa,et al. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains , 1993, Journal of virology.
[35] M. A. Olson,et al. Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen , 2011, Proteins.
[36] D. Granoff. Review of meningococcal group B vaccines. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] M. Nussenzweig,et al. Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120 , 2012, Retrovirology.
[38] D. Burton,et al. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions , 2010, Proceedings of the National Academy of Sciences.
[39] R. Rappuoli,et al. Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity , 2011, Science Translational Medicine.
[40] N. S. Laursen,et al. Highly Conserved Protective Epitopes on Influenza B Viruses , 2012, Science.
[41] Eva K. Lee,et al. Systems Biology of Seasonal Influenza Vaccination in Humans , 2011, Nature Immunology.
[42] S. Ozawa,et al. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. , 2012, Vaccine.
[43] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[44] L. Stamatatos,et al. Interactions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing Activity , 2009, Journal of Virology.
[45] J. Venter,et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.
[46] Peter D. Kwong,et al. Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope , 2004, Journal of Virology.
[47] Bernadette A. Thomas,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.
[48] John Steel,et al. Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.
[49] Gira Bhabha,et al. Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.
[50] D. Baker,et al. Elicitation of structure-specific antibodies by epitope scaffolds , 2010, Proceedings of the National Academy of Sciences.
[51] M. Slifka,et al. Wanted, dead or alive: new viral vaccines. , 2009, Antiviral research.
[52] J. Skehel,et al. A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.
[53] Yih-En Andrew Ban,et al. Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.
[54] Rino Rappuoli,et al. Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.
[55] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.
[56] Thomas Krucker,et al. Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.
[57] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[58] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[59] D. Baker,et al. Computational Design of High-Affinity Epitope Scaffolds by Backbone Grafting of a Linear Epitope , 2011, Journal of Molecular Biology.
[60] E. Reinherz,et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization , 2011, Nature Structural &Molecular Biology.
[61] J. Sodroski,et al. Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1 , 2004, Journal of Virology.
[62] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[63] Mario Roederer,et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.
[64] R. Coffman,et al. Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.
[65] L. Stamatatos,et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.
[66] D. Baker,et al. Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold , 2011, Science.
[67] V. Brusic,et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. , 2008, Immunity.
[68] Martin H. Koldijk,et al. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.
[69] Wah Chiu,et al. Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.
[70] Nimrod D. Rubinstein,et al. Computational characterization of B-cell epitopes. , 2008, Molecular immunology.
[71] S. Reed,et al. Role of adjuvants in modeling the immune response , 2010, Current opinion in HIV and AIDS.
[72] A. West,et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.
[73] I. Messaoudi,et al. Protective immunity following vaccination: How is it defined? , 2008, Human vaccines.
[74] K. Subbarao,et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. , 2010, The Journal of clinical investigation.
[75] Rino Rappuoli,et al. Bridging the knowledge gaps in vaccine design , 2007, Nature Biotechnology.
[76] Yan Liu,et al. A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.
[77] G. Nabel,et al. Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination , 2010, Science.
[78] D. Burton,et al. Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.
[79] Shan Lu. Heterologous prime-boost vaccination. , 2009, Current opinion in immunology.
[80] S. Reed,et al. Targeting TLRs Expands the Antibody Repertoire in Response to a Malaria Vaccine , 2011, Science Translational Medicine.
[81] Magdalini Moutaftsi,et al. Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 Agonist, Promotes Potent Systemic and Mucosal Responses to Intranasal Immunization with HIVgp140 , 2012, PloS one.
[82] R. Rappuoli,et al. Structural vaccinology starts to deliver , 2012, Nature Reviews Microbiology.
[83] John Steel,et al. Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.
[84] J. Mascola,et al. Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04 , 2012, Journal of Virology.
[85] D. Irvine,et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.
[86] J. Mascola,et al. Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region , 2009, Journal of Virology.
[87] Q. Sattentau,et al. Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants , 2012, PloS one.
[88] S. Plotkin. Correlates of Vaccine-Induced Immunity , 2008 .